Journey Medical Corporation

NASDAQ:DERM

Drug Manufacturers - Specialty & Generic

Healthcare
$3.69 +0.99%

+$0.06 today

Market cap
$104.15M
Beta
1.10
P/E (TTM)
-17.0
EPS (TTM)
-$0.35
52W Low $4.31High $9.56

Volume 0.25M

Average 0.28M

DERM Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Journey Medical CorporationNASDAQ: DERM

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of $2.23M (cash outflow) fell 45.2% year over year, behind the +15.5% change in trailing-twelve-month net income. Sequentially, it rose 78.8% from the prior quarter. Over 3 fiscal years it compounded at -27.2% a year.

Context

  • Net income amounted to 18.5% of revenue in FY2025, down 7.7 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 2 analysts of -$3.9M (-65.9%) for the fiscal year ending Dec 2026, a slowdown from the -22.1% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.23M+78.8% QoQ
Last fiscal yearDec 2025
-$11.43M-22.1% YoY
LTMMar 2026
-$9.59M+15.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-45.2%-83.4%-38.1 pp
1 year-22.1%-65.9%-43.8 pp
3-year CAGR-27.2%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(11.43M) USD
Year-over-year change
+22.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How DERM compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.5% is the 7th highest of 10, against a peer median of +24.9%.
  • Net income amounts to 14.8% of revenue for DERM, versus a peer median of 180.3%.
DERM Competitors
Net Income for DERM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€340.16M EUR+84.7%+84.4%7587.8%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$151.77M USD+296.2%—8550.6%
HSDTSolana CompanyLTM Mar 2026$136.85M USD+947.5%+42.7%1427.2%
NYXHNyxoah S.A.LTM Mar 2026€83.7M EUR+24.9%+44.2%512.9%
OSUROraSure Technologies, Inc.LTM Mar 2026$71.83M USD+124.8%-84.4%63.6%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$54.64M USD-17.6%+16.2%167.0%
MDWDMediWound Ltd.LTM Mar 2026$26.1M USD+23.0%+6.8%180.3%
OGIOrganigram Global Inc.LTM Mar 2026CA$25.23M CAD-249.4%—9.2%
DERMJourney Medical CorporationLTM Mar 2026$9.59M USD+15.5%-27.2%14.8%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$8.38M USD-42.0%-24.3%16.4%
Peer median (excluding DERM) —+24.9%+16.2%180.3%

Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.99M)(29.63M)(3.85M)(14.67M)(11.43M)
Depreciation & Amortization2.56M4.37M3.86M3.42M4.72M
Deferred Income Tax1.57M0000
Stock-Based Compensation2.47M4.43M2.61M6.1M6.29M
Change in Working Capital14.71M6.19M(1.66M)(3.77M)(11.9M)
Accounts Receivables768K(5.38M)12.55M4.48M(19.34M)
Inventory(8.46M)1.74M3.95M(4.23M)4.81M
Accounts Payables21.71M14.34M(18.42M)(2.1M)(7.27M)
Other Working Capital686K(4.52M)262K(1.92M)9.91M
Other Non-Cash Items20.51M1.12M4.29M(211K)(123K)
Operating Cash Flow(2.18M)(13.53M)5.24M(9.13M)(12.44M)
Capital Expenditures(10M)(20M)(5M)(15M)0
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(10M)(20M)(5M)(15M)0
Debt Repayment5.05M16.9M(8.95M)8.7M15.73M
Common Stock Issued32.54M142K4.49M8.29M16.93M
Common Stock Repurchased0(371K)000
Dividends Paid00000
Other Financing Activities16.97M(214K)(350K)(50K)(16.43M)
Financing Cash Flow53.02M16.46M(4.8M)16.99M16.23M
Effect of Forex Changes00000
Net Change in Cash40.84M(17.08M)(4.56M)(7.13M)3.79M
Free Cash Flow(12.18M)(33.53M)240K(9.13M)(12.44M)

Journey Medical Corporation

NASDAQ:DERM

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.